IP Library Granted Patent US 7,601,802
Granted Patent B2
US 7,601,802 · App. 11/177,225 · Granted Oct 13, 2009

Cysteine-containing peptides having antioxidant properties

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,601,802
App. No.
11/177,225
Granted
Oct 13, 2009
Kind
B2
Abstract

Cysteine containing amphipathic alpha helices of the exchangeable apolipoproteins, as exemplified by apolipoprotein (apo) A-I Milano (R173C) and apoA-I Paris , (R151C) were found to exhibit potent antioxidant activity on phospholipid surfaces. The addition of a free thiol, at the hydrophobic/hydrophilic interface of an amphipathic alpha helix of synthetic peptides that mimic HDL-related proteins, imparts a unique antioxidant activity to these peptides which inhibits lipid peroxidation and protects phospholipids from water-soluble free radical initiators. These peptides can be used as therapeutic agents to combat cardiovascular disease, ischemia, bone disease and other inflammatory related diseases.

Claims (11)

1. A method of making a non-naturally occurring peptide having antioxidant activity, the method comprising:

producing a peptide of up to 100 amino acids in length comprising an amphipathic alpha helix comprising 18-40 amino acids, wherein the peptide has a cysteine substituted for at least one amino acid residue at or near the polar/nonpolar interface of the alpha helix in comparison to a naturally occurring alpha helix,

wherein the cysteine substitution confers antioxidant activity to the peptide.

2. The method of claim 1 , wherein the peptide is derived from an HDL-associated protein.

3. The method of claim 2 , wherein the HDL-associated protein is selected from the group consisting of: ApoA-I, Apo E3, Apo E4, Apo AV, and paroxonase.

4. The method of claim 1 , wherein the alpha helix comprises a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:17, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:40, SEQ ID NO:48, SEQ ID NO:53, SEQ ID NO:59, SEQ ID NO:65, and SEQ ID NO:75.

5. The method of claim 1 , wherein at least one of the amino acids at positions 7, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 27, or 28 of SEQ ID NO:31 is substituted with a cysteine.

6. The method of claim 1 , wherein at least one of the amino acids at positions 7, 8, 9, or 10 of SEQ ID NO:48 is substituted with a cysteine.

7. The method of claim 1 , wherein the peptide comprises from 18 to 40 amino acids.

8. The method of claim 1 , wherein the peptide comprises from 18 to 20 amino acids.

9. The method of claim 4 , wherein at least one of the amino acids at position 4, 5, 6, 8, 9, 10, 11, 12, 13, 15, 16, or 17 of SEQ ID NO:17 is substituted with a cysteine.

Assignments (1)
CONFIRMATORY LICENSE Recorded May 30, 2006
From: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
To: UNITED STATES DEPARTMENT OF ENERGY
Reel/Frame 017945/0065 →
Continuity (3)
Division 1014223800 · May 8, 2002
Provisional Application 6028994400 · May 9, 2001
Related Publication 20060286632A1 · Dec 21, 2006